Therefore, with an in-depth study of the mechanism for clock proteins and the discovery of selective and potent small molecule modulators, it is believed that in the near future, the ligands of CRYs, REV-ERBs, or RORs will provide first-class treatment for metabolic diseases such as obesity and diabetes. The gene discussed is CLOCK; the disease is metabolic disease.